Entero Healthcare Solutions Ltd's Q3FY25 Quarter Results
- 13 Feb 2025
Result Summary
- Entero Healthcare Solutions Ltd reported a 4.2% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 37.4%.
- Its expenses for the quarter were up by 3.9% QoQ and 34.6% YoY.
- The net profit increased 13.1% QoQ and increased 321.9% YoY.
- The earnings per share (EPS) of Entero Healthcare Solutions Ltd stood at 5.8 during Q3FY25.
Financial Statments for Q3FY25
| (₹ crores) | Q3FY25 | Q2FY25 | Q3FY24 | QoQ (%) | YoY (%) |
|---|---|---|---|---|---|
Total Income | 1366.49 | 1311.97 | 994.42 | 4.2% | 37.4% |
Total Expenses | 1327.05 | 1277.19 | 986.09 | 3.9% | 34.6% |
Profit Before Tax | 39.44 | 34.78 | 8.32 | 13.4% | 374.0% |
Tax | 9.99 | 8.74 | 1.34 | 14.3% | 645.5% |
Profit After Tax | 29.45 | 26.04 | 6.98 | 13.1% | 321.9% |
Earnings Per Share | 5.80 | 5.40 | 1.90 | 7.4% | 205.3% |
Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results
Company Overview
Entero Healthcare Solutions Ltd is a company operating within the healthcare industry, focusing primarily on the distribution and supply of pharmaceutical products. The company is engaged in providing logistics and supply chain solutions to pharmaceutical manufacturers and healthcare providers. Entero Healthcare Solutions Ltd plays a pivotal role in ensuring the availability and timely distribution of pharmaceuticals across various regions. As of the most recent data, the company has not disclosed any major developments or strategic shifts, and any further specific details about the company's operations are not available from the provided information.
Revenue
In the third quarter of fiscal year 2025 (Q3FY25), Entero Healthcare Solutions Ltd reported a total income of ₹1366.49 crores. This figure represents a quarter-over-quarter (QoQ) growth of 4.2% compared to the previous quarter, Q2FY25, where the total income was ₹1311.97 crores. Moreover, there was a notable year-over-year (YoY) increase of 37.4%, as the total income for Q3FY24 was ₹994.42 crores. This substantial growth in revenue highlights a positive trajectory over both the quarter and the year, reflecting an expansion in the company's revenue-generating activities.
Profitability
The company's profitability metrics for Q3FY25 indicate a profit before tax (PBT) of ₹39.44 crores, which marks a significant QoQ increase of 13.4% from ₹34.78 crores in Q2FY25. Year-over-year, there is a remarkable growth of 374.0% from ₹8.32 crores in Q3FY24. After accounting for tax expenses, the profit after tax (PAT) stood at ₹29.45 crores, reflecting a QoQ growth of 13.1% and a YoY increase of 321.9%, compared to ₹26.04 crores in Q2FY25 and ₹6.98 crores in Q3FY24 respectively. The earnings per share (EPS) for Q3FY25 was ₹5.80, up 7.4% QoQ from ₹5.40 and 205.3% YoY from ₹1.90, indicating improved profitability per share over the periods.
Operating Metrics
The operating expenses for Entero Healthcare Solutions Ltd during Q3FY25 totaled ₹1327.05 crores, showing a QoQ growth of 3.9% from ₹1277.19 crores in Q2FY25. On a YoY basis, the expenses increased by 34.6% from ₹986.09 crores in Q3FY24. Despite the increase in total expenses, the company has managed to achieve substantial growth in both its profit before and after tax, highlighting efficient cost management relative to revenue growth. The tax expenditure for the quarter was ₹9.99 crores, reflecting a QoQ increase of 14.3% and a YoY increase of 645.5%, compared to previous periods. This indicates a higher effective tax rate, aligning with the increased profitability of the company.
